

REMARKS

As noted in Paper Number 022004, Applicants have amended the specification to include sequence identifiers. Due to the extensive number of sequence identifiers, Applicants respectfully submit a substitute specification and request that the substitute specification replace the original specification. A marked up version of the specification, indicating changes relative to the original specification, as well as a “clean” substitute specification are submitted herewith. No new matter has been added.

Page 24, lines 10-11 has been further amended to correct a clerical error. Applicants note that 3 nucleotides have been inadvertently omitted from the sequencing primers NTHi-05 and NTHi-06 (page 24, lines 10-11 of the substitute specification) as evident by a 2nd disclosure of the same primer, but this time with the correct sequence (see page 24, lines 15-16 of the substitute specification.). Applicants respectfully submit that support for the amendments can be found by on page 24, lines 15-16, and also in the previously submitted Sequence Listing, i.e., SEQ ID NOs: 63-64.

Applicants have amended the Brief Description of the Drawings to include sequence identifiers, in order to comply with the Sequence Listing Requirements. Applicants respectfully submit that amendments to the Brief Description of the Drawings satisfies that Sequence Listing Requirements for the Figure pages. See, for example, MPEP 2429:

“-Figures can be used to convey information not readily conveyed by the Sequence Listing. The exclusive conformance requirement of 37 CFR 1.821(b) will be relaxed for drawing figures. However, the sequence information so conveyed must still be included in a ‘Sequence Listing’ and the *sequence identifier (SEQ ID NO:X) must be used, either in the drawing or in the ‘Brief Description of the Drawings’* “.


In addition to inclusion of the sequence identifiers, the Brief Description of the Drawings has been amended, for the sake of clarity, to reiterate the connection between the sequence identifier and the sequence disclosed in the Figures. Applicants respectfully submit that

support for the amendments to the Brief Description of the Drawings can be found in Figures 1-5.

Applicants also received in Paper Number 022004 a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures". On that form, Applicants were requested to submit a substitute computer readable form (CFR) of the Sequence Listing. Applicants note, however, that the Sequence Listing, in CFR and hard copy, has not been amended. All sequences found in the current specification were present in the previously submitted Sequence Listing. No modifications have been made. No additional sequences have been added. For that reason, Applicants believe that they are in compliance with 37 CFR 1.821-1.825, and a CFR will not be submitted at this time, as it is duplicative of the record. However, if the Examiner so requests, Applicants would be happy to submit another CFR of the Sequence Listing.

If it would expedite the prosecution of this application, the Examiner is invited to confer with the Applicants' undersigned attorney.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jeffrey A. Sutton". The signature is stylized with a large, looped "J" and "S".

Jeffrey A. Sutton
Attorney for Applicants
Registration Number: 34,028

GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6316
Facsimile (610) 270-5090